Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Thermalin Diabetesinsulin 588 X 395 is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin.
The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH grants.
The new flush of cash will augment Thermalin’s recent $1.5 million Phase 2 SBIR grant that it received recently from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. It plans to begin IND-enabling studies for Flurolog – Thermalin’s highly concentrated, rapid-acting insulin. The drug, ideally taken at meal time, is geared toward patients who need higher insulin doses to control blood sugar. Because it’s so concentrated, it’ll allow insulin pumps to be much smaller, since the needed insulin reservoir will be able to shrink 80 percent.
http://medcitynews.com/2014/07/new-wave-insulin-maker-thermalin-diabetes-raises-5-9m/
The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH grants.
The new flush of cash will augment Thermalin’s recent $1.5 million Phase 2 SBIR grant that it received recently from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. It plans to begin IND-enabling studies for Flurolog – Thermalin’s highly concentrated, rapid-acting insulin. The drug, ideally taken at meal time, is geared toward patients who need higher insulin doses to control blood sugar. Because it’s so concentrated, it’ll allow insulin pumps to be much smaller, since the needed insulin reservoir will be able to shrink 80 percent.
http://medcitynews.com/2014/07/new-wave-insulin-maker-thermalin-diabetes-raises-5-9m/